Neurogene Inc. – Filings and Transcripts

NASDAQ: NGNE
Share price (8/21/26): $38.63
Market cap (8/21/26): $773 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement

Ownership Filter

Trails Edge Capital Partners, LP

Balyasny Asset Management L.P.

Redmile Group, LLC

Cvijic Christine Mikail

Cvijic Christine Mikail

News Filter

Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Material Definitive Agreement, Other Events, Financial Statements or Exhibits

Reports Positive Long-Term Clinical Data From Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Shareholder Vote Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC